<DOC>
	<DOCNO>NCT00796718</DOCNO>
	<brief_summary>This single arm study ass efficacy safety treatment Xeloda plus standard pelvic radiotherapy participant locally advanced rectal cancer . Eligible participant receive Xeloda 825mg/m^2 orally twice daily plus standard radiotherapy 5 week , follow surgery within 6 week completion treatment . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Plus Radiotherapy Participants With Locally Advanced Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , 1880 year age ; rectal cancer ; plan surgery , likely benefit preoperative combine chemoradiotherapy ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 previous radiotherapy chemotherapy colorectal cancer ; clinically significant cardiovascular disease ; significant gastric small intestine disease ; serious uncontrolled active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>